Does Rallies show Form 4 insider transactions for HBIO?

Yes. Rallies tracks HBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HBIO. It does not provide personalized investment advice.

HBIO (Harvard Bioscience Inc) Stock Analysis - Insider Trades

Harvard Bioscience Inc (HBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, HBIO trades at $5.40 with a market cap of $22.55M and a P/E ratio of -5.89. HBIO moved +0.00% today. Year to date, HBIO is -20.98%; over the trailing twelve months it is +60.52%. Its 52-week range spans $2.81 to $28.20. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces HBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HBIO stock inside the company?

Recent HBIO insider activity includes DENELSKY STEPHEN J bought 10.00K, Snider William bought 8.47K, Frost Mark T bought 5.00K, Snider William bought 12.53K, and Duke John D bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HBIO Key Metrics

Key financial metrics for HBIO
Metric	Value
Price	$5.40
Market Cap	$22.55M
P/E Ratio	-5.89
EPS	$-0.91
Dividend Yield	0.00%
52-Week High	$28.20
52-Week Low	$2.81
Volume	0
Avg Volume	0
Revenue (TTM)	$85.53M
Net Income	$-9.78M
Gross Margin	58.42%

Recent HBIO Insider Trades

DENELSKY STEPHEN J bought 10.00K (~$48.70K) on Mar 17, 2026.
Snider William bought 8.47K (~$41.10K) on Mar 17, 2026.
Frost Mark T bought 5.00K (~$25.00K) on Mar 16, 2026.
Snider William bought 12.53K (~$62.50K) on Mar 16, 2026.
Duke John D bought 5.00K (~$25.05K) on Mar 16, 2026.

Latest HBIO News

Harvard Bioscience Q1 Revenues Dip to $20.8M While Gross Margin Rises to 59% — May 12, 2026
Harvard Bioscience Sets 10-for-1 Reverse Split Effective March 13 to Boost Share Price — Mar 9, 2026
Harvard Bioscience Q4 Revenue Tops Guidance at $23.7M, EBITDA Up 27% — Feb 10, 2026

HBIO Analyst Consensus

1 analysts cover HBIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.

Common questions about HBIO

Who is trading HBIO stock inside the company?: Recent HBIO insider activity includes DENELSKY STEPHEN J bought 10.00K, Snider William bought 8.47K, Frost Mark T bought 5.00K, Snider William bought 12.53K, and Duke John D bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HBIO?: Yes. Rallies tracks HBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HBIO. It does not provide personalized investment advice.